Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0125

Congress meeting · Dr. Hiroshi Petit

07 Jan 2026 · Phone · Dr. Hiroshi Petit, MD Anderson Cancer Center · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0125—

Capture insight from this engagement

Location: MD Anderson Cancer Center
Therapeutic area: Nephrology
Country: United States
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Proteinuria as surrogate endpoint

Scientific content used

NPH mechanism-of-action deck

Questions raised

What is the immunoglobulin monitoring recommendation?
Is there any data on APRIL inhibition in FSGS?

Notes

Congress meeting with renal pathologist at MD Anderson Cancer Center. Discussed proteinuria as surrogate endpoint.

Insights captured (1)

Capture insight

INS-0027Medium
Proteinuria as surrogate endpoint
Proteinuria as surrogate endpoint: interest in collaboration reported by renal pathologist (US).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Connect with Clinical Development

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 4
Depth of exchange: 3
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0125

Audit history (0)

All create, update and approval events for this record

No audit events in sample data